ArticleDrug design, development and therapy2025
Study of the Chemical Composition and Anti-Inflammatory Mechanism of Shiyiwei Golden Pill Based on UPLC-Q-TOF/MS and Network Pharmacology.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Luteolin alleviates inflammation by inhibiting the PI3K-Akt-FOXO3a pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A Comprehensive Review of Phenolic Compounds in Horticultural Plants.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Shiyiwei Golden Pill (SYW) is a classic traditional prescription used to treat mKhris-pa according to the theory of Tibetan medicine. At present, SYW is widely used to treat cholecystitis in Tibetan areas. However, the chemical constituents and anti-inflammatory mechanisms are still largely undiscovered. This study aimed to investigate the chemical composition and anti-inflammatory effects of SYW, as well as its potential mechanisms. Methods: The components of SYW were identified using ultrahigh-performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS). The anti-inflammatory effects of SYW were determined on zebrafish and RAW264.7 cell inflammation models. Additionally, we predicted the targets and pathways of SYW to confirm its anti-inflammatory effects using network pharmacology approaches. Finally, a quantitative real-time polymerase chain reaction (qRT-PCR) was performed to validate the expression of genes associated with anti-inflammatory pathways. Results: We identified 94 compounds in SYW, mainly alkaloids, phenols, and flavonoids. SYW inhibited inflammatory cell proliferation and migration in the three zebrafish inflammation models. In the RAW264.7 cell model, SYW suppressed the levels of NO and pro-inflammatory cytokines. In addition, network pharmacology analysis revealed that ALB, IL6, TNF, AKT1, and EGFR were identified as the potential key targets of SYW. KEGG enrichment and qRT-PCR analysis showed that PI3K/Akt/FoxO signaling pathway was involved in the anti-inflammatory effects of SYW. Conclusion: Herein, we identified 94 chemical constituents of SYW and demonstrated that SYW exerts anti-inflammatory effects by regulating the PI3K/Akt/FoxO signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.